An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments

Andrew T. Coxon, Tanner M. Johanns, Gavin Dunn

Research output: Contribution to journalReview articlepeer-review

5 Scopus citations

Abstract

Glioblastoma is a devastating disease with a dismal prognosis. While recent advancements in cancer immunotherapy have led to improvements in treating other types of cancer, patients with glioblastoma have not benefited from these new therapies and techniques. Fortunately, neurosurgeons and oncologists at Washington University School of Medicine conducting a cutting edge clinical trial are looking to overcome these persistent challenges in treating glioblastoma through combining a personalized vaccine with new immunotherapy drugs.

Original languageEnglish
Pages (from-to)45-49
Number of pages5
JournalMissouri Medicine
Volume117
Issue number1
StatePublished - Jan 1 2020

Fingerprint

Dive into the research topics of 'An Innovative Immunotherapy Vaccine with Combination Checkpoint Blockade as a First Line Treatment for Glioblastoma in the Context of Current Treatments'. Together they form a unique fingerprint.

Cite this